ETF PROAI

IGSBvsPPH

iShares 1-5 Year Investment Grade Corporate Bond ETF against VanEck Pharmaceutical ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IGSB 96PPH 116Oct 25Oct 26GROWTH OF $100
Head to head
IGSBPPH
Expense ratio0.040%0.36%
Assets$23.4B$1B
Net flow, 1 month+$251M+$44M
Net flow, 1 year+$2.6B+$325M
Return, YTD-3.4%+4.7%
Return, 1 year-3.6%+15.8%
Avg daily volume5M286K
Holdings389227
ListedJan 5, 2007Feb 1, 2000
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.